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Irritable bowel syndrome (IBS) is a functional bowel disorder and the etiology is not well understood. Currently there is no
cure for IBS and no existing medication induces symptom relief in all patients. IBS-20 is a 20-herb Chinese medicinal formula
that oﬀers beneﬁcial eﬀects in patients with IBS; however, the underlying mechanisms are largely unknown. This study showed
that IBS-20 potently inhibited LPS- or IFNΓ-stimulated expression of pro-inﬂammatory cytokines, as well as classically activated
macrophage marker nitric oxide synthase 2. Similarly, IBS-20 or the component herb Coptis chinensis decreased LPS-stimulated
pro-inﬂammatory cytokine secretion from JAWS II dendritic cells. IBS-20 or the component herbs also blocked or attenuated
the IFNΓ-induced drop in transepithelial electric resistance, an index of permeability, in fully diﬀerentiated Caco-2 monolayer.
Finally, the up-regulation of key inﬂammatory cytokines in inﬂamed colon from TNBS-treated mice was suppressed signiﬁcantly
by orally administrated IBS-20, including IFNΓ and IL-12p40. These data indicate that the anti-inﬂammatory activities of IBS-20
may contribute to the beneﬁcial eﬀects of the herbal extract in patients with IBS, providing a potential mechanism of action for
IBS-20.Inaddition,IBS-20maybeapotentialtherapeuticagentagainstotherTh1-dominantgutpathologiessuchasinﬂammatory
bowel disease.
1.Introduction
IBS is one of the most common gastrointestinal (GI) dis-
orders aﬀecting up to 20% of the adult population and is
characterized by chronic abdominal pain and discomfort as
well as alterations in bowel habits [1]. The lack of success
of the current available therapies using serotonin as a pri-
mary therapeutic target in the management of the major
symptoms may be related to heterogeneity of the etiology
and symptoms of IBS [2] .T h e r ei sn oc u r ef o rI B Sa n dn o
existing medication induces symptom relief in all patients.
Therefore, it is believed that new strategies of developing
eﬀective treatments for IBS should be focused on agents that
can simultaneously act on multiple sites/pathways.
Chinese herbal therapies have been used to treat GI
symptoms for centuries and have provided eﬀective relief
of symptoms in IBS patients. Generally, traditional herbal
formulae contain many diﬀerent components that act on
multiple sites/pathways with potential synergistic eﬀects and
chemical reactions among the component herbs that can
maximize eﬃcacy. IBS-20 is a Chinese medicinal formula
containing 20 herbs that was developed from two traditional
ancient Chinese herbal formulations known as Tong Xie
Yao Fang (Important Prescription for Abdominal Pain and2 Evidence-Based Complementary and Alternative Medicine
Diarrhea) and Zhong Man Fen Xiao Wan (Separate and
Reduce Fullness in the Middle). IBS-20 oﬀered a global
symptom improvement in patients with IBS in a random-
ized, double-blinded, placebo-controlled clinical trial [3]
and is currently on a phase II dose-escalation clinical trial for
IBS patient. Like many other traditional Chinese medicinal
regimes, the mechanisms for the beneﬁcial eﬀects of IBS-20
are unknown.
There is mounting evidence indicating that previous GI
infection is a key risk factor for a subgroup of IBS patients
[4–7]. More recent studies also showed that some degree
of immune activation is present in nearly all IBS patients
tested, regardless of previous history of infection or the type
of disease (constipation, diarrhea, or alternating) [4, 5, 8].
Compoundsthattargettheimmunesystemareanimportant
option in the treatment of a number of GI pathologies, in-
cluding inﬂammatory bowel disease (IBD), but have not
been evaluated fully in IBS. This study was designed,
therefore, to investigate, (i) the eﬀects of IBS-20 on the
cytokine production from innate immune cells stimulated
with inﬂammatory mediators, (ii) the ability of IBS-20 to
block/attenuate the dysregulated barrier function in Caco-2
cell monolayer, and (iii) the anti-inﬂammatory activities
of IBS-20 in the murine model of TNBS-induced colitis.
The results of these studies indicate that IBS-20 has potent
anti-inﬂammatory eﬀects on innate immune cells in vitro as
wellasonmurinemodelofcolitisinvivo.Inaddition,IBS-20
blocks/attenuates the IFNγ-induced disruption of epithelial
barrier function. Thus, the beneﬁcial eﬀects of IBS-20 in
patientswithIBSmaybeattributedtothestronganti-inﬂam-
matory activities of IBS-20 or the component herbs.
2.MaterialsandMethods
2.1. Mice. C57BL/6 mice were purchased from The Jack-
son Laboratories (Bar Harbor, ME). All experiments were
conducted in accordance with principles set forth in the
Guide for Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, National Research Council,
Health and Human Services Publication (National Institutes
of Health 85-23, revised 1996), and the Beltsville Animal
Care and Use Committee, 2003.
2.2. TNBS-Induced Colonic Inﬂammation in Mice. Female,
six-week-old C57BL/6 mice received intrarectal instillation
of TNBS (2mg/mouse in 40% ethanol) to induce colonic
inﬂammation as described [9]. IBS-20 extracts were sus-
pended in saline as the concentration of 50mg/mL. One
milliliter of solution containing 50mg of IBS-20 extracts was
orally administrated to mice (n = 5/group) daily started on
the same day as TNBS. This dose of IBS-20 was equivalent
to the human dose. Control mice were treated with 1mL of
saline and all mice were studied 7 days after treatment.
2.3.PlantMaterials. ThecomponentherbsintheIBS-20for-
mula (Table 1) were acquired in the prescribed proportions
(% w/w) through the Zhixin Chinese Pharmaceutical Co.
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Figure 1: Chromatographic ﬁngerprint of Coptis sinensis rhizomes.
Number in the bracket is the relative retention of the peak to the
marker peak: (1) 0.81, (2) 0.88, (3) 0.89, jatrorrhizine, (4) 0.90, (5)
0.93, coptisine, (6) 0.98, palmatine, (7) marker, berberine.
Ltd, Guangzhou, China. Voucher samples (IBS-01 to IBS-
20) have been deposited at the herbarium of the School of
Chinese Medicine, The Chinese University of Hong Kong
(Shatin, Hong Kong). The individual herbs were identiﬁed
by their Chinese pharmaceutical as well as their scientiﬁc
botanical (Latin binomial) names (Table 1) and botani-
cally authenticated by macroscopic and microscopic means
according to pharmacopoeial methods. In cases where two
or more species have the same oﬃcial pharmaceutical name,
only one species was selected for chemical and biological/
clinical studies. In addition to botanical authentication, the
individual component herbs (illustrated in Figure 1 for Cop-
tis sinensis rhizomes as an example) were chemically char-
acterizedbyHPLCanalysesemployingoneormorereference
markercompoundstoproducecharacteristicqualitativepro-
ﬁles (ﬁngerprints). Additionally, tests for purity as measured
by the contents of foreign matters, total ash, acid-insoluble
ash, water, and alcohol extractives were performed according
to oﬃcial pharmacopoeial methods. The presence of heavy
metals, pesticides, microbes, and fungal toxin (aﬂatoxin)
contamination was also carried out and determined to meet
pharmacopoeial standards as described previously [10].
The twenty dried component herbs were individually
milled or sliced and admixed in the prescribed proportion
(% w/w) as shown in Table 1, followed by extraction with
water under good manufacturing practices (GMP) at the
Hong Kong Institute of Biotechnology. Brieﬂy, the herb
mixture, totaling 400kg, was decocted with 10-fold (w/v) of
boiling distilled water for 60 minutes, cooled and collected.
Fresh boiling water was added to the marc and decocted
for a second time. The cooled extracts were pooled, ﬁltered,
concentrated, and spray dried to obtain a powder (34%
yield w/w based on raw herbs). An aliquot was set aside for
chemical and preclinical biological studies. The remaining
portionwasformulatedwithwater-solublestarch(excipient)
into the clinical product. The HPLC ﬁngerprint of IBS-20
(Figure 2) and the content of selected marker compounds
were determined as previously described [10]. For in vitro
studies, the herbal extracts were processed for removal of
possible contaminating LPS using Detoxi-Gel Endotoxin Re-
moving Gel (Thermo Scientiﬁc, Rockford, IL).
2.4. Reference Marker Compounds and Reagents. Reference
marker compounds (Table 1) for qualitative and quantitative
HPLC analyses were obtained from the National InstituteEvidence-Based Complementary and Alternative Medicine 3
Table 1: Component herbs in the IBS-20 formula and their reference markers.
Pharmaceutical name and
Chinese phonetic name Botanical name and plant part Composition (%)
Reference marker(s)
Qualitative analysis
(HPLC ﬁngerprinting)
Quantitative analysis
(HPLC)
Angelicae Dahuricae Radix
(Bai Zhi)
Angelica dahurica (Fisch.ex Hoﬀ.)
Benth. et Hook. f. (Apiaceae); Root 2 Imperatorin Imperatorin
Artemisiae Scopariae Herba
(Yin Chen)
Artemisia scoparia Waldst. et Kit.
(Asteraceae); Aerial part 13 Chlorogenic acid Chlorogenic acid
Atractylodis Macrocephalae
Rhizoma (Bai Zhu)
Atractylodes macrocephala Koldz.
(Asteraceae); Rhizome 9— —
Aucklandiae Radix
(Mu Xiang)
Aucklandia lappa Decne.
(Asteraceae); Root 3 Costunolide Costunolide;
Dehydrocostus lactone
Bupleuri Radix (Chai Hu) Bupleurum chinense DC.
(Apiaceae); Root 4.5 Saikosaponin a, d Saikosaponin a
Citri Reticulatae
Pericarpium (Chen Pi)
Citrus reticulata Blanco (Rutaceae);
Ripe fruit pericarp 3 Hesperidin Hesperidin
Codonopsis Radix (Dang
Shen)
Codonopsis pilosula Nannf. Var.
modest a (Nannf.) L. T. Shen
(Campanulaceae); Root
7 Lobetyolin Lobetyolin
Coicis Semen (Yi Yi Ren)
Coix lacryma-jobi L.var.ma-yuen
(Roman.) Stapf. (Poaceae); Ripe
kernel
7 Glycerol trioleate Glycerol trioleate
Coptidis Rhizoma
(Huang Lian)
Coptis chinensis Franch.
(Ranunculaceae); Rhizome 3 Berberine Berberine; Palmatine
Fraxini Cortex (Qin Pi) Fraxinus rhynchophylla Hance
(Oleaceae); Branch or stem bark 4.5 Aesculetin Aesculetin; Esculin
Glycyrrhizae Radix et
Rhizoma Praeparata cum
Melle (Zhi Gan Cao)
Glycyrrhiz uralensis
Fisch.(Fabaceae); Root and rhizome 4.5 Glycyrrhizic acid Glycyrrhizic acid
Magnoliae Oﬃcinalis Cortex
(Hou Po)
Magnolia oﬃcinalis Rehd. Et Wils.
(Magnoliaceae); Root, branch and
stem bark
4.5 Magnolol Magnolol; Honokiol
Paeoniae Alba Radix
(Bai Shao)
Paeonia lactiﬂora Pall.
(Paeoniaceae); Root 3 Paeoniﬂorin Paeoniﬂorin
Plantaginis Semen
(Che Qian Zi)
Plantago asiatica L.
(Plantaginaceae); Ripe seed 4.5 — —
Phellodendri Amurensis
Cortex (Guan Huang Bo)
Phellodendron amurense Rupr.
(Rutaceae); Bark 4.5 Berberine Berberine; Palmatine
Pogostemonis Herba
(Guang Huo Xiang)
Pogostemon cablin (Blanco)
Benth.(Lamiaceae); Aerial part 4.5 —
Patchouli alcohol (GC
method was used for
analysis)
Poria (Fu Ling) Poria cocos (Schw.) Wolf
(Polyporaceae); Sclerotium 4.5 — —
Saposhnikoviae Radix
(Fang Feng)
Saposhnikovia divaricata (Turcz.)
Schischk. (Apiaceae); Root 3 5-O-
Methylvisammioside
prim-O-
Glucosylcimifugin;
5-O-
Methylvisammioside
Schisandrae Chinensis
Fructus (Wu Wei Zi)
Schisandra chinensis (Turcz.) Baill.
(Schisandraceae); Ripe fruit 7 Schisandrin Schisandrin
Rhizoma Zingiberis
Praeparatum (Pao Jiang)
Zingiber oﬃcinale Rose
(Zingiberaceae); Prepared rhizome 4.5 6-Gingerol 6-Gingerol
for the Control of Pharmaceutical and Biological Products
(Beijing, China) and were subjected to identity validation by
MSandNMRanalysesandpurity(>98%)analysisbyHPLC-
DAD and/or LC-MS.
2.5. Preparation of Bone Marrow-Derived Macrophages
(BMDM) and Cell Culture. Nonadherent bone marrow mo-
nonuclear cells were obtained from mice by ﬂushing the
marrow from tibia and femurs into HyClone MEM Alpha4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Chromatographic ﬁngerprint of the IBS-20 formula.
The identities of the peaks by LC-MS analysis are (1) Esculin,
(2) Chlorogenic acid, (3) Aesculetin, (4) Paeoniﬂorin, (5) prim-
O-Glucosylcimifugin, (6) Magnoﬂorine, (7) Liquiritin, (8) 5-O-
Methylvisamminoside, (9) Hesperidin, (10) Columbamine, (11)
Jatrorrhizine, (12) Epiberberine, (13) Coptisine, (14) Palmatine,
(15) Berberine, (16) Glycyrrhizic acid, (17) Schisandrin, (18)
Honokiol, (19) Magnolol, and (20) Schisandrin A.
medium (Thermo) containing 10% FBS. Cells were cultured
overnight at 37◦Cw i t h5 %C O 2 in HyClone MEM Alpha
medium to deplete adherent stromal cells. The nonadherent
mononuclear cells were collected, treated with Red Blood
Cell Lysis Buﬀer to deplete red blood cells. These cells were
then cultured in the presence of 20ng/mL recombinant
mouse M-CSF (R&D Systems, Minneapolis, MN) for 7
days to generate fully diﬀerentiated macrophages with the
medium changed every other day. JAWS II (CRL-11904,
ATCC), a murine dendritic cell line, was cultured in the
Alpha minimum essential medium with 20% FBS, 1% P/S
antibiotic, 4mM glutamine, 1mM sodium pyruvate, and
5ng/mL murine GM-CSF. Macrophages and dendritic cells
(DCs) were plated in 6-well plates and treated in tripli-
cates with the herbal extracts of IBS-20 or the individual
components herbs in the presence or absence of inﬂamma-
tory mediators LPS, IFNγ, or both. After 24 hours, cells were
collected in Trizol for RNA isolation while cell-free super-
natants were collected Luminex Assay on cytokine release.
Based on our preliminary experiments, we selected the most
appropriate concentration of LPS for the individual experi-
ments as follows: 1ng/mL for cytokine mRNA expression
of BMDM, 10ng/mL for cytokine release of BMDM, and
2ng/mL for JAWS II cells.
2.6. Microsnap Well Assay for Transepithelial Electrical Resis-
tance (TEER). Caco-2 cells (HTB-37, ATCC), a human
epithelial cell line, were cultured in Eagle’s minimum essen-
tial medium with 20% FBS. 5 × 105 cells per well are seeded
on a 12-well transwell plate with 12mm insert (Costar 3460,
Corning Incorporated) and incubated at 37◦Cwi t h5 %C O 2.
The bottom of the well (basolateral side) was ﬁlled with
1.5mL culture medium and top chamber (apical side) with
0.5mL medium. Cells were a conﬂuent polarized epithelial
monolayer after 10–14 days in culture. The monolayer was
then treated with herbal extracts of IBS-20 or the individual
component herbs added to both apical and basolateral sides
in the presence or absence of IFN-γ (added to the basolateral
side), a well-recognized epithelial barrier disruptor. TEER
Table 2: Primer sequences for real-time quantitative PCR.
Gene Primer sequences (5  to 3 )
IFNγ Forward, TGGCTGTTTCTGGCTGTTACTG
Reverse, AGGTGTGATTCAATGACGCTTATG
IL-1β Forward, TCTATACCTGTCCTGTGTAATG
Reverse, GCTTGTGCTCTGCTTGTG
IL-6 Forward, TCCATCCAGTTGCCTTCTTG
Reverse, TTTCTCATTTCCACGATTTCCC
IL-10 Forward, TCTCCCCTGTGAAAATAAGAG
Reverse, GCCTTGTAGACACCTTGG
IL12p35 Forward, TTGATGATGACCCTGTGCCTTGG
Reverse, GATTCTGAAGTGCTGCGTTGATGG
IL-12p40 Forward, TGAGAACTACAGCACCAGCTTCTT
Reverse, CTTCAAAGGCTTCATCTGCAAGT
IL-23p19 Forward, CAACTTCACACCTCCCTAC
Reverse, CCACTGCTGACTAGAACTC
NOS-2 Forward, CGGAGCCTTTAGACCTCAACA
Reverse, CCCTCGAAGGTGAGCTGAAC
TGF-β Forward, CTAATGGTGGACCGCAACAAC
Reverse, GCACGGGACAGCAATGGG
TLR4 Forward, ACCAAGAACATAGATCTGAGCTTCAA
Reverse, ATGCCATGCCTTGTCTTCAATT
TNFα CCTCCCTCTCATCAGTTCTATGG
Reverse, GGCTACAGGCTTGTCACTCG
was monitored daily before the treatment and then again at
24 and 48 hours after treatment.
2.7. RNA Extraction, cDNA Synthesis, and Real-Time Quan-
titative PCR. Total RNA was extracted from cultured cells
or colon whole tissue as described previously [11]. RNA
samples (2μg) were reverse-transcribed to cDNA using the
First Strand cDNA Synthase Kit (MBI Fermentas, Hanover,
MD) with random hexamer primer. Real-time quantitative
P C R( q P C R )w a sp e r f o r m e do na ni C y c l e rd e t e c t i o ns y s t e m
(Bio-Rad, Hercules, CA) as described. The fold changes in
mRNA expressions for targeted genes were relative to the
respective vehicle groups of mice after normalization to 18S
rRNA. Primers for qPCR were designed by Beacon Designer
7.0 (Premier Biosoft International, Palo Alto, CA) and syn-
thesized by Sigma or the Biopolymer Laboratory of the Uni-
versity of Maryland (Baltimore, MD). The sequences were
listed in Table 2 or as described previously [11].
2.8. Luminex Assay for Cytokine Release. Cell-free super-
natantwascollectedandthecytokinereleasewasdetermined
using Luminex 100 System in the Cytokine Core Lab of the
University of Maryland (Baltimore, MD).
2.9. Data Analysis. Statistical analysis was performed using
one-way ANOVA followed by Newman-Keuls test to com-
paretheresponsesandgeneexpression.Appropriatevehicle-,
time-,andage-matchedcontrolswerealsoincludedthrough-
out the studies.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: IBS-20 inhibited LPS-stimulated expression of pro-inﬂammatory cytokines/mediators in bone marrow-derived macrophages
(BMDMs). BMDMs were treated with LPS (1ng/mL) in the presence or absence of IBS-20 extracts (20 or 100μg/mL). After 24 hours, cells
werecollectedinTrizolformRNAexpressionofTNFα(a),IL-6(b),IL-12p35(c),IL-12p40(d),IL-1β (e),andNOS-2(f)byqPCR. ∗P<0.05
versus respective vehicle (VEH), φP<0.05 versus LPS alone. Data shown in bar graphs are the mean ± s.e.m and representative of at least
two independent experiments.
3. Results
3.1. IBS-20 Potently Inhibits the Expression/Production of Pro-
Inﬂammatory Cytokines in Macrophages. Given the fact that
low-grade inﬂammation is often present in patients with IBS
and many Chinese herbs possess anti-inﬂammatory proper-
ties, we sought to determine if IBS-20 can inhibit the pro-
inﬂammatory cytokine production from macrophages, one
of the major cells involved in inﬂammation. We performed
studies in bone marrow-derived macrophages (BMDMs)
that are generally considered to be a pure population of
mature macrophages and often serve as a valuable cell
model for assessing anti-inﬂammatory activities [12]. Three
diﬀerent concentrations of IBS-20 were initially tested: 20,
100, and 300μg/mL. IBS-20 had no eﬀect on basal cytokine
expression or cell viability at the concentrations of 20 and
100μg/mL (Figure 3) but caused some degrees of cell death
at 300μg/mL. IBS-20 at 20μg/mL had modest inhibitory
eﬀects on LPS-stimulated up-regulation of TNFα,I L - 6 ,
and IL-12p40, a subunit shared by both IL-12 and IL-23
(Figures 3(a), 3(b),a n d3(d)). At 100μg/mL, IBS-20 potently
inhibitedLPS-stimulatedup-regulationofseveralmajorpro-
inﬂammatory cytokines, including IL-6, TNFα, IL-12p35,
and IL-12p40 (Figures 3(a)–3(d)). In contrast, IBS-20 did
not aﬀect the basal or LPS-stimulated cytokine expression
of IL-1β (Figure 3(e)), IFNγ, IL-23p19, or IL-13 (data not
shown). It also was without eﬀect on the anti-inﬂammatory
cytokines, TGFβ or IL-10 (data not shown). These date6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: IBS-20 inhibited cytokines release of TNFα and IL-6 from BMDMs. BMDMs were treated with LPS (10ng/mL) in the presence
or absence of IBS-20 extracts (0.1mg/mL). After 24 hours, cell-free supernatants were collected for cytokine release of TNFα (a) and IL-6
(b) by Luminex Assay. ND: not detected. ∗P<0.05 versus vehicle (VEH) or IBS-20; φP<0.05 versus LPS. Data shown in bar graphs are the
mean ± s.e.m and representative of at least two independent experiments.
indicate that IBS-20 is not a general anti-inﬂammatory
agent,butratheraninhibitorofspeciﬁccytokines/mediators.
Changes in mRNA expression do not always translate into
changes in protein expression; therefore, we measured cyto-
kine release using Luminex Assay. Consistently, the LPS-
stimulated cytokine release of TNFα and IL-6 from
BMDM was signiﬁcantly less when treated with IBS-20
(Figure 4), indicating that IBS-20 inhibits the pro-inﬂam-
matory cytokines at both translational and transcriptional
levels. Notably, IL-12p40 protein was not detectable in the
cellculturesupernatantofBMDMevenafterstimulatedwith
LPS (1ng/mL) for 24 hours (data not shown).
It is well established that macrophages undergo distinct
pathways of activation under diﬀerent cytokine microenvi-
ronments[13].InthepresenceofLPS,macrophagesundergo
classical activation (CAMφ) characterized by the signiﬁcant
up-regulation of inducible nitric oxide synthase (NOS-2)
expression, the speciﬁc molecular marker for inﬂammatory
CAMφ. IBS-20 signiﬁcantly attenuated the LPS-induced up-
regulation of NOS-2 in BMDM (Figure 3(f)), indicating that
IBS-20 can also inﬂuence the phenotypic development of
macrophages.
IFNγ is an important pro-inﬂammatory cytokine pro-
duced mainly by Th1 and antigen-presenting cells (macro-
phage and DC). Increased levels of IFNγ are implicated in
various inﬂammatory pathologies. To investigate whether
IBS-20 can aﬀect the biological activities of IFNγ,w es t i m u -
lated BMDM with IFNγ,L P S ,o rI F N γ + LPS in the pre-
sence or absence of IBS-20. qPCR showed that IFNγ or LPS
alone upregulated the mRNA expression of IL-12p40 and,
when given together, had a synergetic eﬀect (Figure 5(a)).
The presence of IBS-20 signiﬁcantly inhibited the IL-12p40
expression in BMDM stimulated with LPS or IFNγ alone,
or in combination. Conﬁrming the qPCR results, Luminex
assay of cell culture supernatant showed that IBS-20 com-
pletely blocked LPS + IFNγ-induced IL-12p40 release
(Figure 5(b)). Similarly, IBS-20 greatly decreased the IL-6
production in macrophages stimulated with both LPS and
IFNγ (Figure 5(c)).
The biological activities of LPS depend on TLR4, a toll-
like receptor implicated in Th1-dominant inﬂammation. To
further explore the mechanisms by which IBS-20 inhibits
LPS-stimulated cytokine production, we measured the ex-
pression of TLR4. qPCR showed that TLR4 expression was
unaﬀected by either LPS or IBS-20 treatment (data not
shown), indicating that the anti-inﬂammatory activities of
IBS-20 do not involve TLR4.
3.2. IBS-20 Potently Inhibits the Expression/Production of
Proinﬂammatory Cytokines in JASW-II Cells. Dendritic cells
represent another type of major innate immune cells im-
portant for adaptive immunity and aberrant activation of
DC implicated in variety of inﬂammation. To determine
whether IBS-20 aﬀects the activities of DC, we performed
studies on JASW-II cells, a mouse dendritic cell line. Cells
were treated with IBS-20 in the presence or absence of LPS
and cell culture supernatants were collected for Luminex
assay of pro-inﬂammatory cytokine release. Consistent with
its anti-inﬂammatory activities on macrophages, IBS-20
signiﬁcantly decreased LPS-induced IL-6 secretion from
JAWS-II cell (Figure 6). Again, the eﬀect on IL-1β pro-
duction was not apparent due to the very low expression
levelevenafterstimulationwithLPS(Figure 6).OntheotherEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: IBS-20 inhibited the cytokine expression/release from BMDMs stimulated with inﬂammatory mediators. BMDMs were treated
withLPS(10ng/mL),IFNγ (10ng/mL),orbothinthepresenceorabsenceofIBS-20extracts(0.1mg/mL).After24hours,cellswerecollected
in Trizol for mRNA expression of IL-12p40 by qPCR (a). Cell-free supernatants were collected for cytokine release of IL-12p40 (b) or IL-6
(c) by Luminex Assay. ND: not detected. ∗P<0.05 versus respective VEH; φP<0.05 versus respective vehicle. Data shown in bar graphs are
the mean ± s.e.m and representative of at least two independent experiments.
hand, LPS-stimulated TNFα secretion was not suppressed
by IBS-20 (Figure 6).
3.3. Coptis Chinensis Is an Anti-Inﬂammatory Component
Herb of IBS-20. IBS-20 is an herbal formula consisting of 20
component herbs. Among the several herbs that have docu-
mented anti-inﬂammatory activities [14], we selected Coptis
chinensis (Huang Lian, HL) for further testing the eﬀects on
LPS-stimulatedcytokinereleasefromJAWSIIcells.Although
it had no eﬀect on the basal level of cytokine release, Coptis8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀects of IBS-20 on cytokine secretion of JAWS II cells.
Cells were treated with IBS-20 extracts (0.1mg/mL) in the presence
or absence of LPS (2ng/mL) and the cell-free supernatants were
collected after 24-hour treatment. Cytokine secretion of IL-1β,I L -
6, and TNFα was determined by Luminex Assay. ∗P<0.05 versus
respective vehicle or IBS-20; φP<0.05 versus IBS-20. Data shown
inbargrap hsar ethemean±s.e.mandrepresentativeofatleasttwo
independent experiments.
chinensis almost completely abolished the LPS-stimulated
cytokine release of pro-inﬂammatory IL-6, IL-1β,a n dT N F α
(Figures 7(a)–7(c)).
3.4. IBS-20 or the Selected Component Herbs Attenuate/Block
the IFNγ-Induced Epithelial Barrier Dysfunction. Epithelial
cells in the mucosal surface form a monolayer barrier that
limits the exposure of pathogens or products to the under-
lying immune cells; therefore, maintaining an intact mucosal
barrier is arguably one of the most critical factors in immune
homeostasis. Having established the anti-inﬂammatory ac-
tivities of IBS-20 in the innate immune cells, we next deter-
mined if IBS-20 was capable of inﬂuencing epithelial barrier
function. We cultured Caco-2 cells, a human colonic epithe-
lial cell line, and treated them with IBS-20 in the presence
of IFNγ, a well-established epithelial barrier disruptor.
Transepithelial electrical resistance (TEER) was measured as
an index of permeability. Consistent with previous reports,
IFNγ eﬀectively decreased TEER of Caco-2 monolayer after
48-hour treatment indicating an increase in permeability
(Figure 8). The presence of IBS-20 prevented this IFNγ-
induced decrease in TEER, indicating maintenance of nor-
mal barrier function (Figure 8). Two of the individual herbs,
Paeonia lactiﬂora Pall (Bai Shao, BS) and Saposhnikovia
divaricata Schischk (Fang Feng, FF), also signiﬁcantly atten-
uated the IFNγ-induced drop in TEER, while Phellodendron
amurense (Huang Bai, HB) had no eﬀect (Figure 8). It is
noteworthy that neither IBS-20 nor any of the individual
component herbs tested had any eﬀect on the basal TEER.
3.5. IBS-20 Attenuates the TNBS-Induced Upregulation of
Proinﬂammatory Cytokines in Colon. The anti-inﬂammatory
activities of IBS-20 in vitro in both immune and epithelia
cells suggest that IBS-20 may provide beneﬁcial eﬀect for
inﬂammatory disease. We extended our investigation to the
murine model of TNBS-induced colonic inﬂammation. Be-
ginning the day of intracolonic administration of TNBS,
mice were given daily IBS-20 for 7 days via gavage. The
TNBS-induced macroscopic (tissue edema, length, and
weight of colon) and histological abnormalities (crypt dam-
age and inﬂammatory cell inﬁltration) of colon were un-
changedbyIBS-20(datanotshown);however,up-regulation
of two key Th1 cytokines, IFNγ and IL-12p40, in inﬂamed
colon was attenuated signiﬁcantly in mice receiving IBS-20
(Figure 9).
4. Discussion
Herbal therapy has been used in Chinese Medicine for many
thousands of years and has regained popularity over the
last few decades worldwide. Their eﬃcacy and mechanisms
of actions, however, remain largely unknown. The current
study shows that IBS-20, a multicomponent Chinese medic-
inal formula developed from traditional ancient Chinese
herbal formulations, has potent anti-inﬂammatory activities
in both innate immune cells in vitro as well as the TNBS-
inﬂamed colon in vivo. In addition, the herbal formula can
protect the colonic epithelial monolayer from the inﬂam-
matory mediator-induced barrier dysfunction.
The gut harbors the largest immune system in the
body and the mucosa is considered to be the initial site of
interaction with commensal and pathogenic organisms [15].
Even though gut homeostasis is under tight control, immune
dysregulation occurs and contributes to a variety of inﬂam-
matory pathologies [16]. IBS is the most commonly dia-
gnosed gastrointestinal disorder, and recent work implicates
a role of inﬂammation in the pathogenesis of IBS [4, 5, 8].
Indeed, increased levels of pro-inﬂammatory and/or de-
creased levels of anti-inﬂammatory cytokines are found in
the peripheral blood mononuclear cells, circulation, and/or
mucosal samples in patients with IBS [4, 5, 17]. In addition,
increased inﬁltration of immune cells (mostly mast cell
and T lymphocytes) [18–20]o ra b n o r m a la c t i v a t i o no fT / B
cell [8, 21] are observed in the mucosa of patients with
IBS. Through the release of pro-inﬂammatory mediators,
these immune cells interact with, and sensitize, the sensory
and motor neurons, leading to colorectal hypersensitivity
detected in many IBS patients [22, 23].
As one of the major players in gut immunity, macro-
phages are present constitutively in the intestinal lamina
propria[24–26].Undernormalconditions,intestinalmacro-
phages lack or have reduced responses to inﬂammatory
stimuli. During active disease, the number of macrophages
is increased in the lamina propria as a result of recruitment
of circulating monocytes. These recruited macrophages
releaselargeamountsofpro-inﬂammatorycytokines,suchasEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Inhibitory eﬀects of Coptis chinensis (Huang Lian, HL) on the cytokine secretion of JAWS II cells. Cells were treated with Coptis
chinensis extracts (20μg/mL) in the presence or absence of LPS (2ng/mL) and the cell-free supernatants were collected after 24-hour
treatment. Cytokine secretion of TNFα (a), IL-6 (b), and IL-1β (c) was determined by Luminex Assay. ∗P<0.05 versus respective VEH;
φP<0.05 versus HL.
IL-1β, IL-12, TNFα,a n dI F N γ, which are important in both
the onset and development of inﬂammation [25]. Finally,
macrophagescaninﬂuencethediﬀerentiationandexpansion
of inﬂammatory Th1/Th17 eﬀector cells by releasing IL-12
and IFNγ [26, 27]. In this study, IBS-20 potently inhibited
production of pro-inﬂammatory cytokines from BMDM
stimulated by inﬂammatory mediators such as LPS and
IFNγ.
Macrophages express many types of TLRs, including
TLR4 which is responsible for LPS stimulation of large
amounts of pro-inﬂammatory cytokine production [28, 29].
Increased expression of TLR is reported in the colonic
mucosa of animal models of IBS [27]. IBS-20 did not aﬀect
the TLR-4 expression in macrophages, indicating that the
intracellular signaling molecules of TLR-4, rather than the
receptoritself,arethepotentialtargetofIBS-20.LPSactivates
TLR4 signaling by binding to TLR4:MD2 receptor complex,
a process facilitated by the coordination of LPS binding
protein and CD14. It then leads to the activation of MyD88-
dependent and/or independent intracellular signaling path-
way. The MyD88-dependent pathway causes rapid activation
of transcription factors NF-κB and AP-1, and is responsible
for the early production of pro-inﬂammatory cytokines such
as IL-1β and TNFα. The MyD88-independent pathway, on10 Evidence-Based Complementary and Alternative Medicine
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treated with herbal extracts of IBS-20 (100μg/mL) or the individual component herbs (20μg/mL), Paeonia lactiﬂora Pall (Bai Shao, BS),
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Figure 9: Administration of IBS-20 suppresses the up-regulation of pro-inﬂammatory cytokine expression in the inﬂamed colon in vivo.
Mice received intrarectal instillation of TNBS (2mg/mouse in 40% ethanol) to induce colonic inﬂammation. IBS-20 extracts were given to
mice daily via gavage. Mice were euthanized at day 7 after TNBS, and the colon was collected for mRNA expression of cytokines by qPCR.
Results on the expression of IFNγ (a) and IL-12p40 (b) were shown. ∗P<0.05 versus VEH; φP<0.05 versus IBS-20; n = 5f o re a c hg r o u p .Evidence-Based Complementary and Alternative Medicine 11
the other hand, activates IRF3 and is responsible for the
induction of Type 1 interferons and interferon-inducible
genes that are important for antiviral and antibacterial re-
sponses. The distinct eﬀect of IBS-20 on LPS-stimulated
cytokine expression suggests that the herbs may inﬂuence
multiple sites/pathways of TLR-4 intracellular signaling to
inhibit the LPS-induced pro-inﬂammatory cytokine produc-
tion, although more details remain to be fully understood.
Dendritic cells are another major type of innate immune
cells and professional antigen presenting cells that play a
crucial role in both innate and adaptive immunity. Intestinal
DCs reside in mucosa or lymphoid tissues such as Peyer’s
patchesandmesentericlymphnodes.Throughsamplingand
processing numerous luminal antigens from food, micro-
organisms, and their products, mucosal DCs are important
for the immune system to achieve tolerance and maintain
homeostasis. Abnormal DC functions have been associated
with intestinal inﬂammation. The current study showed that
in addition to its anti-inﬂammatory eﬀects on macrophages,
IBS-20 strongly inhibited LPS-stimulated cytokine produc-
tion from JASW II cells, a DC cell line, suggesting a global
anti-inﬂammatory activity of IBS-20 that is likely mediated
by antigen presenting cells. Coptis chinensis is among the
severalcomponent herbs of IBS-20 that have well document-
ed anti-inﬂammatory activities. Previous studies show that
Coptis chinensis extracts or the major alkaloid from Coptis
chinensis can inhibit the expression of various pro-inﬂam-
matory cytokines such as IL-6 and TNFα [14, 30, 31].
Consistently, our study showed that Coptis chinensis aqueous
extracts completely blocked LPS-stimulated cytokine release
of IL-6, IL-1β,a n dT N F α from DC, indicating that Coptis
chinensis is the component herb that contributes, at least in
part, to the anti-inﬂammatory action of IBS-20. It remains
to be determined whether any of other individual herbs has
similar eﬀects.
Control of intestinal permeability is critical to host de-
fense because enhanced permeability facilitates passage of
large numbers of intraluminal bacteria, antigens, or other
pathogen-generated molecules across the mucosal barrier
that trigger immune activation [32]. Evidence indicates
that IBS patients exhibit increased mucosal permeability in
the small intestine or colon irrespective of IBS subtype,
and that is often correlated with the disease severity [32–
35]. In addition, changes in mucosal barrier function and
the resulting immune activation are involved in triggering
visceral hypersensitivity in patients with IBS [18, 22, 33].
This study showed that IBS-20 or the component herbs are
able to preserve normal mucosal barrier function, providing
another mechanism for the beneﬁcial eﬀects in patients. It
would be interesting to identify the molecular targets of IBS-
20 acting through the intracellular signaling and tight junc-
tion proteins that may contribute to herbal eﬀects on epi-
thelial barrier function.
TNBS-induced colonic inﬂammation in mice is a com-
monly used chemically induced model that features up-re-
gulationofpro-inﬂammatorycytokines(IL-1β,IFNγ,TNFα,
IL-12, IL-17A). This model has been used for investigat-
ing the pathogenesis of IBD and testing the anti-inﬂam-
matory activities of agents with therapeutic potential [36].
MacrophageactivationwithincreasedlevelsofTh1cytokines
in the colonic mucosa is another feature of mice treated
with TNBS. In addition, TNBS treatment mimics several
key aspects of symptoms in patients with IBS, including
the increase in mucosal permeability and visceral hyper-
sensitivity in response to colorectal distension [37]. The
underlying mechanisms for the hyperalgesia are not fully
understood but may involve the release of pro-inﬂammatory
mediators interacting with, and sensitizing, the sensory and
motor neurons [38]. Administration of IBS-20 with TNBS
simultaneously abolished or signiﬁcantly attenuated the up-
regulation of pro-inﬂammatory cytokines in the inﬂamed
colon consistent with its anti-inﬂammatory activities. It was
surprising to see that the clinical symptoms or histological
abnormalities of the colon in TNBS-treated mice were not
improved by IBS-20. This could be attributed to a number
of factors relating to the use of IBS-20 in vivo including
the inability to inhibit the TNBS-induced epithelial barrier
breakdown or to block production of IL-1β,am a j o rp r o -
inﬂammatory cytokine implicated in TNBS-induced colonic
inﬂammation.
Collectively, this study demonstrates that IBS-20 pos-
sesses strong anti-inﬂammatory properties. The herbal ex-
tracts not only inhibit the pro-inﬂammatory cytokine pro-
duction from the immune cells but also block the inﬂam-
matory mediator-induced epithelial cell barrier disruption.
Moreover,IBS-20is capableofsuppressingtheup-regulation
of inﬂammatory cytokine in the inﬂamed colon in vivo.
Thus,thebeneﬁcialeﬀectsofIBS-20inpatientswithIBSmay
be attributed to its anti-inﬂammatory activities. It should
be noted that IBS patients are heterogeneous and inﬂam-
mation may only occur in certain subtypes of patients par-
ticularly those with histories of previous infection. These
factors should be taken into account when applying anti-
inﬂammatory therapies to IBS patients. Given the fact that
there are similarities and clinical overlaps between IBS and
other gut inﬂammatory diseases [39], IBS-20 may also be a
potential therapeutic agent against other Th1-dominant gut
pathologies such as IBD.
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